<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <titles>
      <item>
        <chamberCode />
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
        <chamberName />
        <title>Opioid Addiction Risk Transparency Act</title>
      </item>
      <item>
        <chamberCode />
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <chamberName />
        <title>A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.</title>
      </item>
      <item>
        <chamberCode />
        <titleType>Display Title</titleType>
        <parentTitleType />
        <chamberName />
        <title>Opioid Addiction Risk Transparency Act</title>
      </item>
      <item>
        <chamberCode />
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <parentTitleType />
        <chamberName />
        <title>Opioid Addiction Risk Transparency Act</title>
      </item>
    </titles>
    <notes />
    <latestAction>
      <links />
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <actionDate>2017-05-04</actionDate>
    </latestAction>
    <committees>
      <billCommittees>
        <item>
          <systemCode>sshr00</systemCode>
          <subcommittees />
          <activities>
            <item>
              <name>Referred to</name>
              <date>2017-05-04T18:49:05Z</date>
            </item>
          </activities>
          <name>Health, Education, Labor, and Pensions Committee</name>
          <chamber>Senate</chamber>
          <type>Standing</type>
        </item>
      </billCommittees>
    </committees>
    <actions>
      <actionTypeCounts>
        <referredToCommittee>1</referredToCommittee>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <item>
        <actionDate>2017-05-04</actionDate>
        <committee>
          <name>Health, Education, Labor, and Pensions Committee</name>
          <systemCode>sshr00</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <links />
        <type>IntroReferral</type>
        <actionDate>2017-05-04</actionDate>
        <text>Introduced in Senate</text>
        <committee />
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <actionCode>10000</actionCode>
      </item>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
    </actions>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <sponsors>
      <item>
        <fullName>Sen. Hassan, Margaret Wood [D-NH]</fullName>
        <party>D</party>
        <bioguideId>H001076</bioguideId>
        <identifiers>
          <lisID>2302</lisID>
          <gpoId />
          <bioguideId>H001076</bioguideId>
        </identifiers>
        <lastName>Hassan</lastName>
        <byRequestType />
        <middleName>Wood</middleName>
        <firstName>Margaret</firstName>
        <state>NH</state>
      </item>
    </sponsors>
    <recordedVotes />
    <updateDate>2018-08-28T20:26:37Z</updateDate>
    <billNumber>1049</billNumber>
    <title>Opioid Addiction Risk Transparency Act</title>
    <relatedBills>
      <item>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
        <latestTitle>FDA Reauthorization Act of 2017</latestTitle>
        <type>S</type>
        <congress>115</congress>
        <number>934</number>
        <latestAction>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.</text>
          <actionDate>2017-05-11</actionDate>
        </latestAction>
      </item>
    </relatedBills>
    <amendments />
    <version>1.0.0</version>
    <laws />
    <cboCostEstimates />
    <billType>S</billType>
    <createDate>2017-05-05T00:41:44Z</createDate>
    <originChamber>Senate</originChamber>
    <summaries>
      <billSummaries>
        <item>
          <updateDate>2017-05-04T04:00:00Z</updateDate>
          <actionDate>2017-05-04</actionDate>
          <lastSummaryUpdateDate>2018-01-17T21:29:50Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Opioid Addiction Risk Transparency Act</b></p> This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.]]></text>
          <actionDesc>Introduced in Senate</actionDesc>
          <versionCode>00</versionCode>
          <name>Introduced in Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <committeeReports />
    <calendarNumbers />
    <cosponsors>
      <item>
        <bioguideId>Y000064</bioguideId>
        <middleName>C.</middleName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <fullName>Sen. Young, Todd C. [R-IN]</fullName>
        <lastName>Young</lastName>
        <state>IN</state>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <bioguideId>Y000064</bioguideId>
          <lisID>2019</lisID>
          <gpoId>7948</gpoId>
        </identifiers>
        <sponsorshipDate>2017-05-04</sponsorshipDate>
        <firstName>Todd</firstName>
      </item>
    </cosponsors>
    <introducedDate>2017-05-04</introducedDate>
    <congress>115</congress>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Health personnel</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

